Want to see AU:PCK full AI Analyst Report?
Top Page
PainChek Ltd
(Sydney:PCK)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$0.10
▼(-67.24% Downside)
Action:Reiterated
Date:09/11/26
The score is held down primarily by weak financial performance—large ongoing losses, worsening cash burn, and negative equity with added debt—despite strong revenue growth and improved gross margin. Technicals are relatively supportive with price above major moving averages and a positive MACD, but near-overbought indicators temper the signal. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
Rapid Revenue Growth
Rapid revenue expansion indicates increasing adoption of PainChek’s platform and growing commercial reach in its target markets. If sustained, this top-line trajectory can improve operating leverage, support broader enterprise deployments, and provide a foundation for eventual profitability.
Negative Factors
Deep Ongoing Losses
Severe ongoing losses show that the current revenue base remains insufficient to cover operating costs, despite strong sales growth and better gross margins. The absence of an evident path to breakeven limits internal funding capacity and leaves execution of the growth strategy financially dependent.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Growth
Rapid revenue expansion indicates increasing adoption of PainChek’s platform and growing commercial reach in its target markets. If sustained, this top-line trajectory can improve operating leverage, support broader enterprise deployments, and provide a foundation for eventual profitability.
Read all positive factors
PainChek Ltd (PCK) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$20.19M
Dividend YieldN/A
Average Volume (3M)121.20K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth11.45%
EPS Growth0.69%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding209,249,440
10 Day Avg. Volume51,531
30 Day Avg. Volume121,202
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)-15.11
Price to Sales (P/S)5.78
P/FCF Ratio-2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PainChek Ltd Business Overview & Revenue Model
Company Description
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed ...
How the Company Makes Money
PainChek makes money primarily by licensing and selling access to its PainChek software platform to organisations that need to assess and document pain, particularly in aged care and clinical settings. Revenue is typically generated through recurr...
PainChek Ltd Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.74M | 3.36M | 2.67M | 1.95M | 978.57K |
| Gross Profit | 2.64M | 997.74K | 726.66K | 712.51K | -258.82K |
| EBITDA | -9.92M | -7.65M | -9.49M | -8.61M | -6.80M |
| Net Income | -8.94M | -7.67M | -8.31M | -7.57M | -5.72M |
Balance Sheet | |||||
| Total Assets | 7.63M | 2.15M | 4.18M | 2.80M | 6.65M |
| Cash, Cash Equivalents and Short-Term Investments | 5.99M | 1.62M | 3.56M | 2.51M | 6.14M |
| Total Debt | 4.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 9.06M | 3.26M | 2.89M | 2.13M | 1.83M |
| Stockholders Equity | -1.43M | -1.11M | 1.29M | 668.13K | 4.82M |
Cash Flow | |||||
| Free Cash Flow | -9.25M | -6.77M | -7.16M | -6.34M | -7.02M |
| Operating Cash Flow | -9.24M | -6.75M | -7.13M | -6.32M | -7.00M |
| Investing Cash Flow | -14.93K | -12.17K | -34.25K | -12.44K | -21.96K |
| Financing Cash Flow | 13.64M | 4.82M | 8.21M | 2.70M | 1.75M |
PainChek Ltd Technical Analysis
Negative
0.29
Price Trends
0.10
Negative
0.11
Negative
0.16
Negative
Market Momentum
>-0.01
Positive
38.10
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PCK, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.10, and above the 200-day MA of 0.16, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.10 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PCK.
PainChek Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$574.44M | 33.55 | 21.61% | 1.81% | 6.95% | 10.77% | |
61 Neutral | AU$134.98M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$121.68M | -6.54 | -203.69% | ― | -1.53% | 28.29% | |
50 Neutral | AU$17.17M | ― | -578.72% | ― | 113.42% | 29.17% | |
49 Neutral | AU$29.53M | -1.43 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$20.19M | -2.19 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
AU:PCK
PainChek Ltd
0.10
-0.70
-87.98%
AU:CGS
Cogstate Ltd
3.31
0.91
38.03%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.15
-0.07
-30.95%
AU:BMT
Beamtree Holdings Ltd
0.09
-0.12
-57.14%
AU:ALC
Alcidion Group Limited
0.10
0.00
0.00%
AU:ICR
InteliCare Holdings Limited
0.02
<0.01
14.29%
PainChek Ltd Corporate Events
PainChek Director Increases Shareholding Through Performance Rights Conversion
Sep 30, 2026
PainChek Limited has reported a change in director Adam Davey’s interests following the conversion of 48,426 performance rights into fully paid ordinary shares. As a result, Davey’s direct holding increased to 105,084 shares, while his...
PainChek adds 242,130 new shares to ASX quotation
Sep 30, 2026
PainChek Ltd has applied for quotation of 242,130 new ordinary fully paid shares on the Australian Securities Exchange, under the ticker PCK, following the exercise or conversion of existing options or other convertible securities. The modest issu...
PainChek Sets 2026 AGM Date and Outlines Shareholder Participation Rules
Sep 30, 2026
PainChek Ltd has scheduled its Annual General Meeting for shareholders at 3 p.m. AEDT on Wednesday, 4 November 2026, to be held at its Sydney offices. The notice outlines the formal business of the meeting, including resolutions and explanatory ma...
PainChek Details 2026 Corporate Governance Framework and ASX Compliance
Sep 23, 2026
PainChek has released its 2026 Corporate Governance Statement, outlining how its board oversees management and aligns with the ASX Corporate Governance Council’s latest principles and recommendations. The document details formal structures s...
PainChek Eyes Next Growth Phase on Recurring Revenue and U.S. Access
Sep 23, 2026
PainChek signalled that the 2026 financial year marks the start of its next growth phase, leveraging an established customer base and rising recurring revenue. The company highlighted that securing regulatory access in the U.S. and other regions i...
PainChek Details Director Ross Harricks’ Holdings After Board Exit
Sep 8, 2026
PainChek Limited has disclosed a final director’s interest notice following the resignation of director Ross Harricks on 1 September 2026. The filing outlines Harricks’ remaining holdings in the company, including fully paid ordinary s...
PainChek to Brief Investors on Global AI Pain Platform Expansion and U.S. Growth Strategy
Sep 3, 2026
PainChek Ltd, a healthcare technology company specialising in AI-driven pain assessment tools, is expanding its presence across key international healthcare markets following regulatory clearances in regions including Australia, Europe, and the Un...
PainChek posts higher revenue but deeper loss as going-concern flagged
Aug 28, 2026
PainChek Ltd reported total revenue of $4.9 million for the year ended 30 June 2026, a modest increase of 2% on the prior year, supported by higher core revenue and interest income but offset by a reduction in grants. The company’s net loss ...
PainChek flags growth momentum and U.S. push ahead of investor webinar
Aug 7, 2026
PainChek Ltd, a medical device and AI-enabled pain assessment specialist, is expanding its global footprint with regulatory clearances across multiple regions including recent FDA De Novo clearance in the United States, and has built a substantial...
PainChek Updates Performance Rights Following Share Consolidation
Aug 5, 2026
PainChek Ltd has updated its previously reported figures for unquoted performance rights following a recent share consolidation, revising the allocations for several key individuals, including J. Murray, R. Harricks, C. Payne and A. Davey. The tot...
PainChek Updates Director Adam Davey’s Equity and Performance Rights Holdings
Aug 5, 2026
PainChek Limited has disclosed a change in director Adam Davey’s interests in the company’s securities, reflecting an updated mix of fully paid ordinary shares and newly issued performance rights. The adjustments include both direct an...
PainChek turns market access into revenue as U.S. rollout begins
Jul 29, 2026
PainChek reported steady operational growth in the June quarter, with implemented licences rising 5.9% to 90,198 and implemented annual recurring revenue reaching $4.46 million across nearly 2,000 active customer sites. Clinical usage continued to...
PainChek boosts cash reserves with $1.1m R&D tax refund to drive global AI pain platform
Jul 21, 2026
PainChek Ltd, an ASX-listed health technology company, develops AI-enabled pain assessment and monitoring applications that serve people who cannot reliably self-report pain, those who can, and those whose ability fluctuates. Its flagship PainChek...
PainChek Discloses Final Director Interest Following Board Departure
Jul 8, 2026
PainChek Limited has disclosed that Philip Daffas ceased to be a director on 6 July 2026, lodging a final director’s interest notice with the ASX. The filing details his remaining holdings in fully paid ordinary shares and performance rights...
PainChek Reshapes Leadership to Drive Post-FDA U.S. Growth
Jul 6, 2026
PainChek Ltd has announced an immediate change in leadership, with long-serving CEO and Managing Director Philip Daffas stepping down as part of a planned transition tied to the company’s Financial Year 2027 strategy following FDA De Novo cl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.